Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">IPO Radar: No IPOs Opening Today, Two Expected to Price Tonight; AppDynamics to be Acquired by Cisco (CSCO)<strong>IPOs Opening Today</strong>:<br/> <ul><li><em>No IPOs Opening Today</em>.</li></ul><p><br/> <strong>Upcoming IPOs:<br/> </strong></p><ul><li><strong>January 26: AnaptysBio (ANAB)</strong> — The biotech developing first-in-class antibody product candidates focused on unmet medical needs in inflammation and immuno-oncology is expected to price its 4.0 million share IPO within a range of $14-$16.</li></ul><ul><li><strong>January 26: ObsEva (OBSV)</strong> — The clinical-stage biopharmaceutical company developing therapeutics for conditions that compromise a woman's reproductive health is expected to price its 6.5 million share IPO within a range of $14-$16.</li></ul><ul><li><strong>January 27: JELD-WEN (JELD)</strong> — The leading door and window manufacturer is expected to price its 25.0 million share IPO within a range of $16-$18.</li></ul><ul><li><strong>January 27: Jagged Peak Energy (JAG)</strong> — The oil & natural gas company focused on acquiring & developing unconventional assets in Southern Delaware Basin is expected to price its 38.2 million share IPO within a range of 16-$18.</li></ul><ul><li><strong>January 27: REV Group (REVG)</strong> — The designer, manufacturer, and distributor of specialty vehicles & aftermarket parts is expected to price its 12.5 million share IPO within a range of $19-$21.</li></ul><ul><li><strong>January 27: Jounce Therapeutics (JNCE)</strong> — The clinical stage immunotherapy focused on transforming treatment of cancer by enabling immune system to attack tumors is expected to price its 5.4 million share IPO within a range of $13-$15.</li></ul><ul><li><strong>January 27: Visterra (VIST)</strong> — The clinical-stage biopharma focused on designing anti-body-based therapies intended to be as effective as single-dose administration is expected to price its 3.9 million share IPO within a range of $12-$14.</li></ul></td> </tr></table>"